Table 3

Results of the proportional hazards model for cardiovascular hospitalisation and mortality and cardiovascular hospitalisation (n = 1760) in relation to allopurinol exposure, showing relative hazard with 95% confidence intervals in brackets

CV hospitalisation (n=566)Mortality or cardiovascular hospitalisation (n=1002)
UnadjustedAdjustedUnadjustedAdjusted
*p < 0.1; **p < 0.05; ***p < 0.01; ****p < 0.001.
Allopurinol exposure
    Recent low dose v never1.64 (1.16 to 2.32)***1.23 (0.86 to 1.76)1.41 (1.06 to 1.86)**1.14 (0.86 to 1.53)
    Longstanding low dose v never2.64 (1.79 to 3.90)****2.31 (1.55 to 3.46)****2.15 (1.56 to 2.96)****1.71 (1.23 to 2.38)***
    Longstanding high dose v never1.20 (0.74 to 1.94)1.13 (0.69 to 1.86)1.05 (0.72 to 1.54)0.96 (0.64 to 1.42)
    Longstanding high dose v longstanding   low dose0.45 (0.25 to 0.83)**0.49 (0.26 to 0.91)**0.49 (0.30 to 0.80)***0.56 (0.34 to 0.92)**
Loop diuretic dose
    Medium v low1.58 (1.32 to 1.89)****1.32 (1.10 to 1.59)***1.56 (1.37 to 1.79)****1.41 (1.23 to 1.62)****
    High v low3.09 (2.29 to 4.16)****1.78 (1.28 to 2.47)****2.58 (2.02 to 3.28)****2.04 (1.57 to 2.66)****
Age (+ 10 years)1.04 (0.96 to 1.12)1.20 (1.09 to 1.31)****1.20 (1.13 to 1.28)****1.27 (1.19 to 1.36)****
Men v women1.02 (0.87 to 1.21)0.93 (0.78 to 1.11)1.12 (0.99 to 1.26)*1.14 (1.00 to 1.30)**
Social deprivation (+ 1 category)1.13 (1.07 to 1.19)****1.12 (1.06 to 1.18)****1.05 (1.01 to 1.09)**1.07 (1.03 to 1.12)****
Number of prior MIs (+ 1)1.22 (1.13 to 1.32)****1.13 (1.04 to 1.22)***1.09 (1.03 to 1.16)***1.11 (1.04 to 1.18)***
Diabetes0.90 (0.67 to 1.22)0.79 (0.58 to 1.07)0.48 (0.36 to 0.65)****0.48 (0.35 to 0.65)****
History
    Use of NSAIDs1.17 (0.81 to 1.68)1.02 (0.70 to 1.48)1.51 (1.18 to 1.93)****1.34 (1.04 to 1.72)**
    Use of thiazides1.14 (0.79 to 1.63)1.00 (0.69 to 1.45)1.14 (0.87 to 1.50)1.04 (0.79 to 1.37)
    Respiratory illness1.26 (1.06 to 1.51)***1.07 (0.89 to 1.29)1.46 (1.29 to 1.66)****1.24 (1.08 to 1.42)***
    Renal disease0.70 (0.51 to 0.95)0.67 (0.49 to 0.91)**1.01 (0.82 to 1.23)0.90 (0.74 to 1.10)
    Hypertension1.23 (0.89 to 1.70)1.08 (0.78 to 1.51)1.26 (0.99 to 1.61)*1.20 (0.94 to 1.55)
Drugs in concurrent use
    Aspirin1.11 (0.94 to 1.31)1.05 (0.88 to 1.25)0.83 (0.74 to 0.94)***0.84 (0.74 to 0.96)**
    Anticoagulants1.69 (1.34 to 2.14)****1.30 (1.01 to 1.68)**1.22 (1.00 to 1.49)1.05 (0.85 to 1.29)
    ACE inhibitors1.92 (1.63 to 2.26)****1.71 (1.41 to 2.07)****1.30 (1.15 to 1.48)****1.19 (1.03 to 1.38)**
    β Blockers0.94 (0.76 to 1.16)1.09 (0.87 to 1.36)0.69 (0.58 to 0.82)****0.87 (0.73 to 1.05)
    Nitrates1.87 (1.52 to 2.30)****1.65 (1.33 to 2.04)****1.09 (0.95 to 1.25)1.09 (0.94 to 1.25)
    Digoxin1.59 (1.33 to 1.90)****1.25 (1.03 to 1.52)**1.44 (1.26 to 1.66)****1.13 (0.98 to 1.31)
    K+ sparing diuretics1.02 (0.86 to 1.21)1.18 (0.98 to 1.42)*0.97 (0.85 to 1.10)0.95 (0.83 to 1.09)
    Antiarrhythmics1.85 (1.34 to 2.54)****1.46 (1.05 to 2.03)**1.20 (0.90 to 1.61)1.03 (0.77 to 1.39)